CA2456976A1 - Expandable gastric retention device - Google Patents
Expandable gastric retention device Download PDFInfo
- Publication number
- CA2456976A1 CA2456976A1 CA002456976A CA2456976A CA2456976A1 CA 2456976 A1 CA2456976 A1 CA 2456976A1 CA 002456976 A CA002456976 A CA 002456976A CA 2456976 A CA2456976 A CA 2456976A CA 2456976 A1 CA2456976 A1 CA 2456976A1
- Authority
- CA
- Canada
- Prior art keywords
- agents
- retention device
- gastric retention
- gastric
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Jellies, Jams, And Syrups (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31307801P | 2001-08-16 | 2001-08-16 | |
US60/313,078 | 2001-08-16 | ||
PCT/US2001/046146 WO2003015745A1 (en) | 2001-08-16 | 2001-10-22 | Expandable gastric retention device |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2456976A1 true CA2456976A1 (en) | 2003-02-27 |
Family
ID=23214285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002456976A Abandoned CA2456976A1 (en) | 2001-08-16 | 2001-10-22 | Expandable gastric retention device |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1416914A1 (pt) |
JP (1) | JP2005501097A (pt) |
KR (1) | KR20040032918A (pt) |
CN (1) | CN1543337A (pt) |
BR (1) | BR0117123A (pt) |
CA (1) | CA2456976A1 (pt) |
CO (1) | CO5670360A2 (pt) |
IL (1) | IL160363A0 (pt) |
MX (1) | MXPA04001388A (pt) |
NO (1) | NO20040611L (pt) |
NZ (1) | NZ531461A (pt) |
PL (1) | PL368327A1 (pt) |
WO (1) | WO2003015745A1 (pt) |
ZA (1) | ZA200402066B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045308A2 (en) | 2001-11-21 | 2003-06-05 | E-Z-Em, Inc. | Formulations for use in medical or diagnostic procedures |
CA2550983C (en) * | 2003-12-24 | 2013-09-17 | Advancis Pharmaceutical Corporation | Enhanced absorption of modified release dosage forms |
US7785291B2 (en) | 2005-03-01 | 2010-08-31 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
US7699863B2 (en) | 2005-03-01 | 2010-04-20 | Tulip Medical Ltd. | Bioerodible self-deployable intragastric implants |
KR20090053783A (ko) * | 2006-07-19 | 2009-05-27 | 스미스클라인 비참 코포레이션 | 감마 섬광조영술 평가를 위한 제형의 방사선표지 방법 |
CN102552103B (zh) * | 2010-12-20 | 2013-11-20 | 西安力邦医药科技有限责任公司 | 拉米夫定固体分散体、其制备方法、药物组合物和用途 |
US10507127B2 (en) | 2012-06-07 | 2019-12-17 | Epitomee Medical Ltd. | Expandable device |
EP3091962B1 (en) | 2013-12-05 | 2022-06-08 | Epitomee Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
EP3725357A1 (en) | 2014-06-11 | 2020-10-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
WO2016178971A1 (en) | 2015-05-01 | 2016-11-10 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
KR20180090881A (ko) | 2015-12-08 | 2018-08-13 | 린드라 인코퍼레이티드 | 위 체류 시스템을 위한 기하 구성형태 |
AU2017268840B2 (en) | 2016-05-27 | 2022-02-10 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
AU2017336154B2 (en) | 2016-09-30 | 2023-11-09 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
WO2018227147A1 (en) | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
US11337919B2 (en) * | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release |
TR201914116A2 (tr) * | 2019-09-17 | 2021-04-21 | Univ Yeditepe | Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4764380A (en) * | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
US5232704A (en) * | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
ES2234139T3 (es) * | 1997-08-11 | 2005-06-16 | Alza Corporation | Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica. |
EA004443B1 (ru) * | 1998-09-14 | 2004-04-29 | Рэнбакси Лабораториз Лимитед | Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день |
JP2000256216A (ja) * | 1999-03-04 | 2000-09-19 | Meiji Milk Prod Co Ltd | ゲル組成物 |
HUP0301465A3 (en) * | 2000-06-23 | 2006-07-28 | Teva Pharma | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
-
2001
- 2001-10-22 JP JP2003520705A patent/JP2005501097A/ja not_active Withdrawn
- 2001-10-22 BR BR0117123-2A patent/BR0117123A/pt not_active IP Right Cessation
- 2001-10-22 CA CA002456976A patent/CA2456976A1/en not_active Abandoned
- 2001-10-22 NZ NZ531461A patent/NZ531461A/en unknown
- 2001-10-22 IL IL16036301A patent/IL160363A0/xx unknown
- 2001-10-22 PL PL01368327A patent/PL368327A1/xx not_active Application Discontinuation
- 2001-10-22 KR KR10-2004-7002254A patent/KR20040032918A/ko not_active Application Discontinuation
- 2001-10-22 MX MXPA04001388A patent/MXPA04001388A/es not_active Application Discontinuation
- 2001-10-22 WO PCT/US2001/046146 patent/WO2003015745A1/en active Application Filing
- 2001-10-22 CN CNA018235441A patent/CN1543337A/zh active Pending
- 2001-10-22 EP EP01995328A patent/EP1416914A1/en not_active Withdrawn
-
2004
- 2004-02-11 NO NO20040611A patent/NO20040611L/no not_active Application Discontinuation
- 2004-03-12 CO CO04023075A patent/CO5670360A2/es not_active Application Discontinuation
- 2004-03-15 ZA ZA200402066A patent/ZA200402066B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005501097A (ja) | 2005-01-13 |
MXPA04001388A (es) | 2004-05-27 |
CN1543337A (zh) | 2004-11-03 |
IL160363A0 (en) | 2004-07-25 |
BR0117123A (pt) | 2004-09-28 |
NZ531461A (en) | 2008-03-28 |
WO2003015745A1 (en) | 2003-02-27 |
PL368327A1 (en) | 2005-03-21 |
ZA200402066B (en) | 2005-05-09 |
NO20040611L (no) | 2004-04-16 |
CO5670360A2 (es) | 2006-08-31 |
EP1416914A1 (en) | 2004-05-12 |
KR20040032918A (ko) | 2004-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040219186A1 (en) | Expandable gastric retention device | |
JP3382950B2 (ja) | 医薬品用の徐放性マトリックス | |
Shaha et al. | An overview of a gastro-retentive floating drug delivery system | |
KR100618234B1 (ko) | 다공성 입자를 포함하는 제형 | |
EP1750717B1 (en) | Controlled release pharmaceutical compositions with improved bioavailability | |
CA2456976A1 (en) | Expandable gastric retention device | |
AU2009313867A1 (en) | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof | |
WO2003035177A2 (en) | Optimal polymer mixtures for gastric retentive tablets | |
AU2002337974A1 (en) | Optimal polymer mixtures for gastric retentive tablets | |
Vasave | A REVIEW ON: FLOATING DRUG DELIVERY SYSTEM | |
US20240299304A1 (en) | A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained | |
JP2018500278A (ja) | 外部粘膜に適用する剤形物品 | |
JP3122478B2 (ja) | 下部消化管放出型経口製剤 | |
JP4224866B2 (ja) | 溶解時間を制御した基剤 | |
AU2002225872A1 (en) | Expandable gastric retention device | |
Katakam et al. | Floating drug delivery systems: a review | |
AU2014368504B2 (en) | Gastro-retentive oral pharmaceutical compositions | |
Kanakagiri | Sustained Release Floating Matrix Tablets of Ciprofloxacin Using Combination of Different Polymers | |
Singh et al. | Gastroretentive Delivery | |
JPWO2019039420A1 (ja) | 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |